499 assets in Hepatocellular Carcinoma

Therapeutic assets addressing Hepatocellular Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Apsolol Hepatocellular Carcinoma	AHS Cancer Control Alberta	P4	B (60)
Benmelstobart Hepatocellular Carcinoma	Nanfang Hospital, Southern Medical University	P3	B (60)
Capecitabine Hepatocellular Carcinoma	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	P3	B (60)
Celecoxib Hepatocellular Carcinoma	Emory University	P4	B (60)
Cetuximab Hepatocellular Carcinoma	Sanofi	P2	B (60)
Durvalumab Hepatocellular Carcinoma	Amit Mahipal	P3	B (60)
Entecavir Hepatocellular Carcinoma	Sun Yat-sen University	P4	B (60)
Nad(Sup +) Hepatocellular Carcinoma	Anhui Provincial Hospital	P4	B (60)
Tenofovir Disoproxil Fumarate Hepatocellular Carcinoma	Ningbo No.2 Hospital	P4	B (60)
Thalidomide Hepatocellular Carcinoma	Shanghai Zhongshan Hospital	P3	B (60)
Huachansu Hepatocellular Carcinoma	Beijing Shenogen Biomedical Co., Ltd	P3	B (59)
Pegargiminase Hepatocellular Carcinoma	Chang Gung Memorial Hospital	P3	B (59)
Pentapeptide-1 Hepatocellular Carcinoma	Second Affiliated Hospital of Soochow University	P3	B (59)
Serplulimab Hepatocellular Carcinoma	Shanghai Henlius Biotech	P3	B (59)
Shr-8068 Hepatocellular Carcinoma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P3	B (59)
Tacrolimus Hepatocellular Carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P4	B (59)
Volitinib Hepatocellular Carcinoma	AstraZeneca	P3	B (59)
Azathioprine Hepatocellular Carcinoma	Baylor Research Institute	P4	B (58)
Denosumab Hepatocellular Carcinoma	Tongji Hospital	P3	B (58)
Docetaxel Hepatocellular Carcinoma	Merck Sharp & Dohme LLC	P3	B (58)
Etoposide Hepatocellular Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P3	B (58)
Fludarabine Hepatocellular Carcinoma	Roswell Park Cancer Institute	P2	B (58)
Fludeoxyglucose Hepatocellular Carcinoma	National Cancer Institute (NCI)	P3	B (58)
Immuncell-Lc Hepatocellular Carcinoma	GC Cell Corporation	P3	B (58)
Immunoglobulin G4 [234-Proline], Anti-(Human Protein Garp-Transforming Growth Factor ?1 Complex) (Human Monoclonal Abbv-151 ?4-Chain), Disulfide With Human Monoclonal Abbv-151 ?-Chain, Dimer Hepatocellular Carcinoma	AbbVie	P2/3	B (58)
Propofol Hepatocellular Carcinoma	Iuliu Hatieganu University of Medicine and Pharmacy	P4	B (58)
Raltitrexed Hepatocellular Carcinoma	Zhujiang Hospital	P3	B (58)
Relatlimab Hepatocellular Carcinoma	Bristol-Myers Squibb	P2	B (58)
Tirelizumab Hepatocellular Carcinoma	Chen Xiaoping	P4	B (58)
Vincristine Sulfate Hepatocellular Carcinoma	Children's Oncology Group	P3	B (58)
Vitamin D Hepatocellular Carcinoma	Taoyuan General Hospital	P4	B (58)
Warfarin Hepatocellular Carcinoma	Mansoura University	P4	B (58)
Yttrium (90 Y) Hepatocellular Carcinoma	Second Affiliated Hospital of Guangzhou Medical University	P3	B (58)
Axitinib Hepatocellular Carcinoma	University of Texas Southwestern Medical Center	P2	B (57)
Finotonlimab Hepatocellular Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2/3	B (57)
hlx13 Hepatocellular Carcinoma	Shanghai Henlius Biotech	P3	B (57)
Indocyanine Green Hepatocellular Carcinoma	University of Florida	P2	B (57)
Losartan Hepatocellular Carcinoma	Second Affiliated Hospital of Xi'an Jiaotong University	P4	B (57)
Pegylated-Interferon .Alfa. 2B (Peg-Ifn) Hepatocellular Carcinoma	Ningbo No.2 Hospital	P3	B (57)
Tas-102 Hepatocellular Carcinoma	Symphogen A/S	P3	B (57)
Biejia-Ruangan Compound Hepatocellular Carcinoma	Nanfang Hospital, Southern Medical University	P4	B (56)
Enoxaparin Hepatocellular Carcinoma	Mansoura University	P4	B (56)
Hydroxychloroquine Hepatocellular Carcinoma	VA Office of Research and Development	P2	B (56)
Sufentanyl Hepatocellular Carcinoma	The First Affiliated Hospital with Nanjing Medical University	P4	B (56)
188re-sss lipiodol Hepatocellular Carcinoma	Center Eugene Marquis	P2	CCC (55)
FCH Hepatocellular Carcinoma	Queen's Medical Center	P3	CCC (55)
ga-68 dolacga Hepatocellular Carcinoma	National Atomic Research Institute, Taiwan	P2	CCC (55)
Genetically-Modified Oncolytic Type 5 Adenovirus Which Selectively Replicates In Tumor Cells Containing Dysfunctional P53 Gene (H101) Hepatocellular Carcinoma	Fudan University	P3	CCC (55)
Nanocrystalline Megestrol Acetate Suspension Hepatocellular Carcinoma	Nanfang Hospital, Southern Medical University	P3	CCC (55)
Rilvegostomig Hepatocellular Carcinoma	AstraZeneca	P3	CCC (55)

Showing 51 to 100 of 499 assets

PreviousPage 2 of 10Next